Literature DB >> 24508819

Fragile X syndrome neurobiology translates into rational therapy.

Sien Braat1, R Frank Kooy2.   

Abstract

Causal genetic defects have been identified for various neurodevelopmental disorders. A key example in this respect is fragile X syndrome, one of the most frequent genetic causes of intellectual disability and autism. Since the discovery of the causal gene, insights into the underlying pathophysiological mechanisms have increased exponentially. Over the past years, defects were discovered in pathways that are potentially amendable by pharmacological treatment. These findings have inspired the initiation of clinical trials in patients. The targeted pathways converge in part with those of related neurodevelopmental disorders raising hopes that the treatments developed for this specific disorder might be more broadly applicable.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24508819     DOI: 10.1016/j.drudis.2014.01.013

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  13 in total

1.  Overrepresentation of genetic variation in the AnkyrinG interactome is related to a range of neurodevelopmental disorders.

Authors:  Ilse M van der Werf; Sandra Jansen; Petra F de Vries; Amber Gerstmans; Maartje van de Vorst; Anke Van Dijck; Bert B A de Vries; Christian Gilissen; Alexander Hoischen; Lisenka E L M Vissers; R Frank Kooy; Geert Vandeweyer
Journal:  Eur J Hum Genet       Date:  2020-07-10       Impact factor: 4.246

2.  Validating and Applying the CSBS-ITC in Neurogenetic Syndromes.

Authors:  Lisa R Hamrick; Bridgette L Tonnsen
Journal:  Am J Intellect Dev Disabil       Date:  2019-05

3.  The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome.

Authors:  Sien Braat; Charlotte D'Hulst; Inge Heulens; Silvia De Rubeis; Edwin Mientjes; David L Nelson; Rob Willemsen; Claudia Bagni; Debby Van Dam; Peter P De Deyn; R Frank Kooy
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 4.  Monogenic mouse models of autism spectrum disorders: Common mechanisms and missing links.

Authors:  S W Hulbert; Y-H Jiang
Journal:  Neuroscience       Date:  2015-12-28       Impact factor: 3.590

Review 5.  Modulation of the GABAergic pathway for the treatment of fragile X syndrome.

Authors:  Reymundo Lozano; Emma B Hare; Randi J Hagerman
Journal:  Neuropsychiatr Dis Treat       Date:  2014-09-16       Impact factor: 2.570

6.  GABAB receptor upregulates fragile X mental retardation protein expression in neurons.

Authors:  Wenhua Zhang; Chanjuan Xu; Haijun Tu; Yunyun Wang; Qian Sun; Ping Hu; Yongjian Hu; Philippe Rondard; Jianfeng Liu
Journal:  Sci Rep       Date:  2015-05-28       Impact factor: 4.379

Review 7.  Neuronal Cytoskeleton in Intellectual Disability: From Systems Biology and Modeling to Therapeutic Opportunities.

Authors:  Carla Liaci; Mattia Camera; Giovanni Caslini; Simona Rando; Salvatore Contino; Valentino Romano; Giorgio R Merlo
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

8.  Positron Emission Tomography (PET) Quantification of GABAA Receptors in the Brain of Fragile X Patients.

Authors:  Charlotte D'Hulst; Inge Heulens; Nathalie Van der Aa; Karolien Goffin; Michel Koole; Kathleen Porke; Marc Van De Velde; Liesbeth Rooms; Wim Van Paesschen; Hilde Van Esch; Koen Van Laere; R Frank Kooy
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

Review 9.  Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder.

Authors:  Richard E Frye
Journal:  Drug Healthc Patient Saf       Date:  2014-05-10

Review 10.  Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes.

Authors:  Hansen Wang; Sandipan Pati; Lucas Pozzo-Miller; Laurie C Doering
Journal:  Front Cell Neurosci       Date:  2015-02-26       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.